Yes I understand that, but do you imagine the study design will be appreciably different from the sparsentan study? 300 patients to 2 years isn't cheap, and you have to be able to go the distance as interim approval isn't a given, as retrophin saw.
when comparing cost studies remember most pivotal studies in immunology or something like this have primary endpoints at 16-24 weeks, not 108
Yes I understand that, but do you imagine the study design will...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
-0.035(6.42%) |
Mkt cap ! $280.3M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.0¢ | 50.0¢ | $1.454M | 2.822M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 544899 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 104681 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |